232 related articles for article (PubMed ID: 30686641)
1. Sacubitril/Valsartan in Adult Congenital Heart Disease Patients With Chronic Heart Failure - A Single Centre Case Series and Call for an International Registry.
Appadurai V; Thoreau J; Malpas T; Nicolae M
Heart Lung Circ; 2020 Jan; 29(1):137-141. PubMed ID: 30686641
[TBL] [Abstract][Full Text] [Related]
2. Sacubitril/valsartan for heart failure in adults with complex congenital heart disease.
Maurer SJ; Pujol Salvador C; Schiele S; Hager A; Ewert P; Tutarel O
Int J Cardiol; 2020 Feb; 300():137-140. PubMed ID: 31242968
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
[TBL] [Abstract][Full Text] [Related]
4. Early Experience With Sacubitril/Valsartan in Adult Patients With Congenital Heart Disease.
Lluri G; Lin J; Reardon L; Miner P; Whalen K; Aboulhosn J
World J Pediatr Congenit Heart Surg; 2019 May; 10(3):292-295. PubMed ID: 31084317
[TBL] [Abstract][Full Text] [Related]
5. Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study).
Shaddy R; Canter C; Halnon N; Kochilas L; Rossano J; Bonnet D; Bush C; Zhao Z; Kantor P; Burch M; Chen F
Am Heart J; 2017 Nov; 193():23-34. PubMed ID: 29129252
[TBL] [Abstract][Full Text] [Related]
6. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
[TBL] [Abstract][Full Text] [Related]
7. Insights into implementation of sacubitril/valsartan into clinical practice.
Martens P; Beliën H; Dupont M; Mullens W
ESC Heart Fail; 2018 Jun; 5(3):275-283. PubMed ID: 29464879
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
[TBL] [Abstract][Full Text] [Related]
9. Interaction Between Sacubitril and Valsartan in Preventing Heart Failure Induced by Aortic Valve Insufficiency in Rats.
Maslov MY; Foianini S; Mayer D; Orlov MV; Lovich MA
J Card Fail; 2019 Nov; 25(11):921-931. PubMed ID: 31539619
[TBL] [Abstract][Full Text] [Related]
10. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.
Martens P; Beliën H; Dupont M; Vandervoort P; Mullens W
Cardiovasc Ther; 2018 Aug; 36(4):e12435. PubMed ID: 29771478
[TBL] [Abstract][Full Text] [Related]
11. Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF.
Vaduganathan M; Claggett BL; Desai AS; Anker SD; Perrone SV; Janssens S; Milicic D; Arango JL; Packer M; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2020 Jan; 75(3):245-254. PubMed ID: 31726194
[TBL] [Abstract][Full Text] [Related]
12. Impact of sacubitril/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience.
Monzo L; Gaudio C; Cicogna F; Tota C; Petronilli V; Mennuni S; De Ruvo E; Calò L
Eur Rev Med Pharmacol Sci; 2021 Sep; 25(18):5690-5700. PubMed ID: 34604961
[TBL] [Abstract][Full Text] [Related]
13. Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
McCormack PL
Drugs; 2016 Mar; 76(3):387-96. PubMed ID: 26873495
[TBL] [Abstract][Full Text] [Related]
14. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
[TBL] [Abstract][Full Text] [Related]
15. "Real World" Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry.
Simpson J; Benson L; Jhund PS; Dahlström U; McMurray JJV; Lund LH
Cardiovasc Drugs Ther; 2019 Jun; 33(3):315-322. PubMed ID: 30903545
[TBL] [Abstract][Full Text] [Related]
16. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
Böhm M; Young R; Jhund PS; Solomon SD; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Packer M; McMurray JJV
Eur Heart J; 2017 Apr; 38(15):1132-1143. PubMed ID: 28158398
[TBL] [Abstract][Full Text] [Related]
17. Assessing suitability for sacubitril-valsartan therapy in an Irish cohort: challenges and opportunities.
Daly A; Coughlan JJ; Mross T; Wafer M; O'Connor A; Liston R
Ir J Med Sci; 2019 Nov; 188(4):1169-1174. PubMed ID: 30796605
[TBL] [Abstract][Full Text] [Related]
18. Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization: Findings From the GWTG-HF Registry (Get With The Guidelines-Heart Failure).
Parikh KS; Lippmann SJ; Greiner M; Heidenreich PA; Yancy CW; Fonarow GC; Hernandez AF
Circulation; 2017 May; 135(21):2077-2080. PubMed ID: 28533321
[No Abstract] [Full Text] [Related]
19. The use of sacubitril/valsartan in anthracycline-induced cardiomyopathy: A mini case series.
Sheppard CE; Anwar M
J Oncol Pharm Pract; 2019 Jul; 25(5):1231-1234. PubMed ID: 29945530
[TBL] [Abstract][Full Text] [Related]
20. Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States.
DeVore AD; Hill CL; Thomas L; Sharma PP; Albert NM; Butler J; Patterson JH; Spertus JA; Williams FB; Duffy CI; McCague K; Hernandez AF; Fonarow GC
Circ Heart Fail; 2018 Sep; 11(9):e005400. PubMed ID: 30354360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
